{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-001500","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.651562+00:00","generated_at":"2026-06-22T10:35:37.008006+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Teva Q3 revenue falls 8% to $3.6B; non-GAAP EPS $0.59 flat; opioid settlement progress","bullets":["Revenue $3.595B (-8% YoY, -2% in local currency); GAAP EPS $0.05; non-GAAP EPS $0.59 (flat YoY).","2022 revenue guidance cut to $14.8-15.4B (prev $15.0-15.6B) due to FX; all other guidance affirmed.","Opioid litigation: substantial progress toward nationwide settlement; agreement in principle with NY AG; reserve updated.","AUSTEDO U.S. revenue +30% YoY, on track for ~$1B annual; AJOVY gains share in U.S., Europe, Japan.","Cash from operations $543M; free cash flow $685M; non-GAAP tax rate outlook revised to 12-14%."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-001500","json":"https://secwatch.observer/filing/0001157523-22-001500.json","markdown":"https://secwatch.observer/filing/0001157523-22-001500.md","text":"https://secwatch.observer/filing/0001157523-22-001500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000115752322001500/0001157523-22-001500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000115752322001500/a52958636.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T10:35:37.008006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"493a9726e8dff5e3ee107597d45ce33f11e5a25c","claim":"TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended September 30, 2022 results: revenue $3,595 million, net income GAAP diluted EPS of $0.05, EPS Non-GAAP diluted EPS of $0.59. Guidance reaffirmed.","evidence_excerpt":"(EXHIBIT 99.1) --- EX-99.1 2 a52958636ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Teva Reports Third Quarter 2022 Financial Results Key financial highlights and outlook Revenues of $3.6 billion GAAP diluted EPS of $0.05 Non-GAAP diluted EPS of $0.59 Cash flow generated from operating activities of $543 million Free cash flow of $685 million 2022 revenues outlook revised","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818686/000115752322001500/0001157523-22-001500-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$3,595 million"},{"label":"Net income","value":"GAAP diluted EPS of $0.05"},{"label":"EPS","value":"Non-GAAP diluted EPS of $0.59"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}